



[Science Education Patient Care & Advocacy](#)
[Our Society](#) [Our Mission, Vision & Values](#) [Equality, Diversity & Inclusion](#) [EBMT](#)
[Membership 2021](#) [Organisational Structure 2021](#) [Financial Highlights 2021](#) [EBMT](#)
[Partners](#)

Breadcrumb

1. [Home](#)

Entity Print



Ibrahim Yakoub-Agha
CMWP Chair
France

Major achievements

2021 was another year of virtual meetings for the CMWP in the context of the ongoing COVID-19 pandemic. The first scientific and educational meetings took place on Friday 29th and Saturday 30th January. We reviewed and discussed ongoing and planned studies within the six subcommittees: (1) Myelodysplasia

including CMML (2) Plasma Cell Diseases (3) Ph. Neg Myeloproliferative Disorders (4) CML/CLL and (6) Practice Harmonisation and Guidelines. The comprehensive educational talks on Saturday consisted of a series of focused sessions on Myelofibrosis by Czerw (Gliwice) and Polverelli (Brescia), Myeloma by Beksac (Ankara) and San Miguel (Navarra), and Myelodysplastic Syndromes by Scheid (Koln) and Platzbecker (Leipzig). Claire Roddie (London) then provided us with a state-of-the-art overview of CAR T-cell therapy in multiple myeloma and Marie Jose Kersten (Amsterdam) spoke on the management of infections in CAR T patients. The final session on CLL was provided by van Gelder (Maastricht) and Gauthier (Seattle).

Our second scientific and educational meeting of 2021 was held in late September and was a great success, thanks to the excellent technical support provided by our colleagues from the EBMT Education and Events Department. This special extended Education event covered a broad range of topics over eight hours of presentations and panel discussions. A highlight was our first session on statistical analysis during which we were provided with comprehensive overviews on Concepts by Iacobelli (Rome) and de Wreede (Leiden), Methods by de Wreede (Leiden) and Data by Gras, Koster and Eikema (All Leiden). Thanks as always are due to our excellent colleagues in Data Management in Leiden without whom none of our studies would be possible.

Principal research studies

[MDS ATG versus Post-Cy in unrelated donors](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Myelodysplastic \(MDS\) or MDS/MPN](#)

[Group](#)

[Chronic Malignancies Working Party \(CMWP\)](#)

[Type of treatment](#)

[Allogeneic - Unrelated](#)

[Principal investigator](#)

[Yves Chalandon, Marie Robin](#)

[Impact of Specific Adverse Cytogenetic Features on Outcomes after Allogeneic](#)

[Hematopoietic Cell Transplantation in Myelodysplastic Syndrome with Very Poor Risk](#)

[Cytogenetics: A Study from the Chronic Malignancies Working Party of EBMT](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Myelodysplastic \(MDS\) or MDS/MPN](#)

[Group](#)

[Chronic Malignancies Working Party \(CMWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Xavier Poiré](#)

Key publications

[2021](#)

[Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT](#)

[Group](#)

[Chronic Malignancies Working Party \(CMWP\)](#)

[1st listed author](#)

[Avichai Shimoni](#)

[Journal](#)

[Br J Haematol.](#)

[2021](#)

[Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation](#)

[Group](#)

[Chronic Malignancies Working Party \(CMWP\)](#)

[1st listed author](#)

[Firoozeh Sahebi](#)


[Journal](#)

[Transplant Cell Ther.](#)

[2021](#)

[Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and](#)

[relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party](#)
[Group](#)
[Chronic Malignancies Working Party \(CMWP\)](#)
[1st listed author](#)
[Donal P McLornan](#)
[Journal](#)
[Leukemia.](#)
[2021](#)
[Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT](#)
[Group](#)
[Chronic Malignancies Working Party \(CMWP\)](#)
[1st listed author](#)
[Tomasz Czerw](#)
[Journal](#)
[Bone Marrow Transplant.](#)
[2021](#)
[Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry](#)
[Group](#)
[Chronic Malignancies Working Party \(CMWP\)](#)
[1st listed author](#)
[Juan-Carlos Hernández-Boluda](#)
[Journal](#)
[Am J Hematol.](#)
[See the full list of the CMWP 2021 publications](#)



2019 2020 2021

Oral presentations	9	1	7
Poster presentations	8	12	5
Educational events	1	2	2

Major educational events



[Event](#)

[Chronic Malignancies Working Party Educational Meeting](#)

[Sep 24, 2021 - Sep 25, 2021 / VIRTUAL MEETING](#)

[Discover more](#)